Ovarian cancer (OC) is one of the most lethal malignant gynecologic tumors, characterized
by an uncertain presentation and poor outcomes. With or without neoadjuvant …

Simple Summary With an overall 5-year survival of only 20% for advanced-stage ovarian
cancer patients, enduring and effective therapies are a highly unmet clinical need. Current …

With the advent of combined immunotherapies, personalized dendritic cell (DC)-based
vaccination could integrate the current standard of care for the treatment of a large variety of …

Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death.
Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and …

Purpose: The successful implementation of immune checkpoint inhibitors (ICI) in the clinical
management of various solid tumors has raised considerable expectations for patients with …

Surgery and chemotherapy are standard treatments in ovarian cancer, but patients have a
high rate of relapse. Dendritic cell (DC)-based vaccines are a new treatment option for …

Identification of tumor-specific target antigens has been a major hurdlefor the treatment of
malignant disease by vaccination or immunotherapy. A second challenge has been the …

Immune-based therapies that induce remarkable and durable responses against melanoma
and lung cancer have unfortunately demonstrated limited success in ovarian cancer …

Ovarian cancer remains the deadliest of all gynecologic malignancies. Our expanding
knowledge of ovarian cancer immunology has allowed the development of therapies that …

Objective DCVAC/OvCa is an active cellular immunotherapy designed to stimulate an
immune response against ovarian cancer. We explored the safety and efficacy of …